AcelRx Pharmaceuticals(ACRX) - 2024 Q2 - Quarterly Results

Financial Performance - The cash, cash equivalents, and investments balance was $14.0 million as of June 30, 2024, an increase from$9.4 million at the end of 2023[22]. - Combined R&D and SG&A expenses for Q2 2024 totaled $4.3 million, slightly up from$4.2 million in Q2 2023, primarily due to increased costs associated with Niyad development[7]. - The net loss from continuing operations for Q2 2024 was $3.8 million, an improvement from a net loss of$4.4 million in Q2 2023[8]. - Net loss attributable to common shareholders for Q2 2024 was $3.8 million, or$0.15 per share, compared to a net loss of $4.4 million, or$0.40 per share, in Q2 2023[9]. - The company recognized a change in fair value of the warrant liability, contributing to the net loss reduction in Q2 2024[8]. - Talphera's total assets increased to $24.9 million as of June 30, 2024, compared to$20.4 million at the end of 2023[22]. Clinical Development - Talphera initiated patient screening at multiple clinical sites for the NEPHRO CRRT registrational study, which will enroll 166 patients across up to 14 sites[5]. - Talphera received FDA approval to increase the maximum number of study sites for the NEPHRO study from 10 to 14, which is expected to expedite the study's completion[2]. - The primary endpoint of the NEPHRO study is the mean post-filter activated clotting time for circuits infused with nafamostat compared to placebo over the first 24 hours[5]. - Talphera's lead product candidate, Niyad™, is being studied as an anticoagulant for the extracorporeal circuit and has received Breakthrough Device Designation from the FDA[11].